RxDoctor Payments Data

Robert Clower, MD

Urology · Watkinsville, GANPI 1437243177

Payments from drug & device makers

$547in general payments, 2019–2025

Across 33 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$149
  • AbbVie$68
  • Laborie Medical Technologies Corp.$60
  • Rochester Medical Corporation$47
  • Boston Scientific$41
  • Calyxo, Inc.$40
  • plus $143 from 6 others

What the payments were for

  • Food & beverage$547100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson10$149
AbbVie3$68
Laborie Medical Technologies Corp.2$60
Rochester Medical Corporation3$47
Boston Scientific3$41
Calyxo, Inc.2$40
Agiliti Surgical, Inc.2$36
Astellas Pharma US Inc2$35
Verity Pharmaceuticals Inc.2$29
Abbott2$24
Mission Pharmacal Company1$13
Ambu Inc.1$6

How this compares

$547 in reported general payments places this provider in the 20th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$20,005
Medicare patients
143
Services billed
411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron14$11,319
Solifenacin Succinate81$2,375
Tamsulosin Hcl82$496
Finasteride12$193
Oxybutynin Chloride ErOxybutynin Chloride11$117
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$36
Meloxicam19$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$35$11,31914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 369 urology providers in Georgia.

Other urology in Watkinsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →